Try our Advanced Search for more refined results
Life Sciences - December, 2019
241 articles
- Hottest Legal Industry Guest Topics Of 2019
- Maryland Legislator Accused In Medical Pot Bribery Scheme
- Zetia Buyers' Lose Antitrust Claims Against Merck, Glenmark
- China Poised To Cut Hundreds Of Tariffs As Tensions Cool
- St. Louis Jury Clears J&J For Its 2nd Talc Win In A Week
- Feds Back Bayer's Bid To Undo $25M Monsanto Verdict
- Sanofi Latest To Tell Full Fed. Circ. Arthrex Changed The Law
- J&J Asks St. Louis Talc Jury To Stand Up For Corporations
- Biggest Developments Of 2019 In Antitrust Cases
- 9th Circ. Told Attys Wrongly Sanctioned In Roundup Trial
- Ex-Genentech Workers Can't Ditch Trade Secret Charges
- Taxation With Representation: Cleary, Skadden, Weil
- FDA Can Keep Regulating Genetically Modified Salmon
- Aegerion Sales Rep Found Guilty In $1.8M Drug Fraud
- This Year's Robust M&A Activity Will Likely Continue In 2020
- DEA, FDA Shut Down 44 Websites Selling Illegal Vapes
- Health & Life Sciences At The High Court: A Decade In Review
- Celgene Can't Shake Shareholder Suit Over Drug Trial
- The Trial Results That Made An Impact In 2019
- The Year In Cannabis Case Law: Major Pot Rulings From 2019
- Health Hires: Goodwin, Manatt, Garfunkel Wild
- PTAB Blocks Pharma Co.'s Repetitive Challenge To Iron Patent
- Senate Passes $1.4T Spending Package To Avert Shutdown
- Jones Day Reps PolyOne In $1.45B Deal For Clariant Unit
- House Approves Retooled North American Trade Accord
- Anthem Settles Class Action Over Autism Coverage Limits
- Scandals, Court Battles That Rocked New Jersey In 2019
- CBD Co.'s Atty Sanctioned In SEC Illicit Stock Sale Suit
- Ill. Insurance Coverage Cases From 2019 Settle Key Questions
- Roche Wants Russian Drug Co. Sanctioned In Antitrust Fight
- IP Pro Rejoins Harness Dickey In Boost To Texas Office
- The Top Bankruptcy Cases Of 2019
- Bayer Drops Trade Secret Suit Against Fired Scientist
- Vape Bans, Investigations And Hemp: 2019 In Pot Regulation
- Chancery Blocks Arbitration In Dow-Chemours Cleanup Battle
- Feds Want 15 Years For Convicted Insys Founder
- 5 Trends That Rocked The Legal Industry In 2019
- The Biggest Massachusetts Cases Of 2019
- The Biggest Patent Rulings Of 2019
- SEC Says Disbarred NY Attys Must Face PixarBio Merger Suit
- Two Agencies, Two 'Nascent Competitor' Merger Challenges
- J&J Exec Testifies FDA's Asbestos Finding Was Fluke
- Allergan Breast Implant Risk MDL Heading To NJ
- EU Clears Danaher $21B GE Biopharma Buy With Divestitures
- Boston Scientific Can't Nix $275M Merger With Device Maker
- Valeant Urges Fed. Circ. To Revive Lawsuit Over Jublia
- Ra Pharma's $2.1B Sale Hits Merger Review Snag At FTC
- Trade Group Urges Justices To Avoid Ark. Benefits Law Fight
- Chancellor Vexed By DuPont, Chemours Spinoff 'Chaos Derby'
- HHS Backs Drug Imports Amid White House Pressure
- Roundup Atty Charged With $200M Corporate Extortion Plot
- 3rd. Circ. Reverses GSK Win In Avandia Marketing Suit
- Fla. House, Cos. Back State's Medical Pot Licensing Rules
- Sens. Say DEA's 8B Opioid Production Quota Is Too High
- Feds Accuse CVS, Omnicare Of Prescription Fraud Scheme
- Impax Can't Use 'Unrelated Benefits,' AGs Tell 5th Circ.
- Ex-Theranos CEO Says Indictment 'Flunks The Constitution'
- Bipartisan Bill Would Have Pharmacies Fork Over Info To DEA
- Sacklers Withdrew $10B From Purdue, Bankruptcy Probe Says
- 10th Circ. Revives Medical Pot Inmate's Prison Challenge
- Judging A Book: Hinojosa Reviews 'Crimes And Punishments'
- Full Fed. Circ. Urged By All Sides To Rethink Arthrex
- Bausch Launches $1.25B Bond Offering To Pay For Settlement
- FTC Challenges Illumina's $1B DNA Sequencing Buy
- Eagle, Eli Lilly Drop Dueling Cancer Drug Patent Claims
- Kentucky Tax Talk: A New Governor's New Tax Ideas
- EpiPen Buyers Seek Class Status In ERISA Suit
- House Panel Greenlights Revised North American Trade Pact
- Loestrin Makers Settle Pay-For-Delay Suit With Direct Buyers
- 'Locality Lawsuits' Threaten The Civil Justice System
- $1.4T Gov't Funding Deal Has Border Wall, Generics, Pensions
- Roche-Spark $4.8B Merger Clears US, UK Regulatory Hurdles
- FDA Escapes Constitutional Challenge Of E-Cig Regulation
- Fed. Circ. Won't Revisit Patent Ruling On Weight Loss Pill
- Health Care Taxes Would Be Repealed Under Spending Plan
- Calif. Jury Finds J&J Not To Blame For Woman's Cancer
- Bausch Will Pay $1.2B To End Valeant-Era Stock Suit
- Actos Buyers Fight Takeda Appeal Bid In Drug Delay Case
- Cleary, Skadden Use Reverse Morris Trust To Forge $45B Co.
- Home Depot Wants Out Of Roundup Cancer Warning Suit
- Sienna Biopharma Seeks To Convert Its Ch. 11 Case
- Fed. Circ. Backs Amgen's $70M Patent Win Over Epogen
- Enablement For Life Sciences Patents Requires Sweat Equity
- Ill. Recreational Cannabis Law Brings Risks For Employers
- Ariz. Medical Pot Dispensary Can't Nix Rival's Registration
- Dems Urge USPTO To Probe Allegations Against Gilead
- Endo's $82.5M Deal In Suit Over Opioid Drug Gets Final OK
- Shareholders Sue Cardinal Health Execs Over Opioid Crisis
- Feds Press For Massive $306M Restitution In Insys Exec Trial
- North American Trade Pact Vote Could Come Wednesday
- Patients Say Rescheduling Pot Would Be A Step Backward
- Mass. Cannabis Vape Sales To Resume Under New Rules
- 5 Noncompete Rulings From 2019 Attorneys Should Know
- Taxation With Representation: Mayer, Sullivan, Covington
- Investor Sues To Block Foamix-Menlo All-Stock Merger
- Drug-Pricing Bill Threatens Robust Generics Industry
- Jury Says Kite Pharma Owes $752M For Infringing Patent
- 2020 Will Be A Year Of Decision For States
- Plaintiffs Experts' Cred At Stake In J&J Talc Trial Closings
- Jury Told Juno's Bid For $752M Patent Damages 'Just Crazy'
- Orexo Loses Bid For New Trial Over Teva's Suboxone Generic
- Calif. Judge Offers Tips On Winning Alice Invalidity Motions
- 2nd Circ. Says NY Opioid Fee Fight May Belong In State Court
- Ill. Latest To Sue Juul For Deceptively Marketing To Minors
- Rite Aid Beats FCA Suit Over Alleged Billing Scheme
- When DOJ Seeks Dismissals Of Life Sciences FCA Cases
- Senate Confirms Lung Cancer Doctor To Lead FDA
- Cleary Gottlieb Reps 3M In $650M Sale Of Drug Delivery Biz
- House Passes Democrats' Bill To Tamp Down Drug Prices
- High-Profile CEOs Urge 'Economy-Wide Action' On Paid Leave
- Calif. County DA Sharply Criticized In 2nd Circ.
- Investor Wants To Block $9.7B Novartis-Medicines Co. Deal
- Duke Asks Fed. Circ. For PTAB Redo On Muscle Treatment IP
- NJ Employment Legislation Had A Blockbuster Year
- Jury Told Patent Typo Shouldn't Get Kite Off $752M Hook
- Jones Day Says Pharma Client Owes $5.3M In Legal Bills
- Former NY Attys Want Out Of SEC's PixarBio Merger Suit
- US Trustee Says Jevic Kills Alston's $1M Deal In Imerys Ch. 11
- 3 Potential Speed Bumps For North American Trade Pact
- AstraZeneca Escapes Biotech Firm's $33.8M Lifted-Data Suit
- BakerHostetler Says Pharma Execs Can't Sue For Illegal Gains
- Fed. Circ. Affirms Actavis Infringed Anti-Nausea Drug Patent
- Momenta To Pay $35M To Exit Blood Clot Drug Antitrust Suit
- Calif. Fights Bid To Block Pay-For-Delay Law
- CBD Seller Says Farm Bill Tethers Case To Federal Court
- Pathologist Testifies He Found J&J Talc In Woman's Ovary
- CBD Co. Can't Escape Securities Class Action
- Ex-Novartis Exec Denied More Atty Fees In Whistleblower Row
- FTC Defends Impax Pay-For-Delay Ruling At 5th Circ.
- Fla. Court Won't Dismiss Pelvic Mesh Discovery Complaint
- Strategies To Maintain Privilege In Crisis Response Scenarios
- 9th Circ. Won't Revive Ex-Abbott Worker's Benefits Challenge
- The Rise Of Patent Wars In Europe's Gene Therapy Space
- Mass. PE Shop Omega Nabs $438M For Life Sciences Fund
- Supreme Court Strikes Down USPTO Atty Fee Rule
- Ex-Kite CEO Undermines Testimony Of Pharma Co.'s Founder
- Trade Deal Changes May Set New Course But Stir Discontent
- FDA's E-Cigarette Regulations Upheld By DC Circ.
- Cannabis Equipment Supplier Says It Was Stiffed On Bill
- NuVasive Tells 1st Circ. Noncompete Law Can't Help Ex-Rep
- FTC Looks Closer At $7.6B Bid To Forge Animal Health Giant
- Clinical Biopharma Sienna OK'd To Sell IP In Ch. 11
- 3 Firms Vie To Lead Chemours Stock-Drop Suit
- 3 Strategies To Manage Case Scope In ANDA Patent Litigation
- Proskauer Steers Perceptive Advisors' $210M Venture Fund
- GLAAD Urges Facebook To Drop Law Firms' HIV Drug Ads
- States Demand Purdue Fight Opioid Crisis With 9-Point Plan
- Revamped North American Trade Deal Set For Hill Vote
- FDA Wants Vape Group's Suit Over E-Cig Deadline Axed
- Juno's Expert Pegs Patent License Value At $752M In Kite Trial
- Ex-NY Rep. Chris Collins Settles SEC Insider Trading Claims
- SG Says Justices Should Use Athena Case To Redo Mayo
- Full Fed. Circ. Won't Review Celgene's Retroactive IPRs
- High Court Won't Review ITC's Refusal To Probe Ad Claims
- How To Ward Off Nonclient Suits Over Lawyers' Speech
- J&J Talc Supplier Imerys Asks For More Time On Ch. 11 Plan
- Cannabis Co. Sued For $150M Over Effort To Devalue Rival
- Navigating The Regulatory Environment For CBD Marketing
- Allergan Aims To Sink Suit Over Generics Antitrust Claims
- California Continues To Set State Environmental Law Trends
- Product Liability Claims Can Be A Global Threat To Cos.
- Ex-Health Care Co. Exec Pleads Guilty To Wire Fraud
- Covington, Skadden Steer Merck's $2.7B Deal For ArQule
- Counterfeit Good Policing In 2019 Was Redefined By Tech
- Workers Say Teva 401(k) Mismanagement Cost Them Millions
- Weil, Cooley Steer Sanofi's $2.5B Cancer Therapy Buy
- High Court Won't Hear Arizona's Opioid Suit Against Sacklers
- Fla. Asks High Court To Find Medical Pot Regs Constitutional
- Gilead Fights Monopoly Accusation Over HIV Prevention Drug
- Talc Jury Told They Could Save Lives By Ruling Against J&J
- Judge Says FDA Can't Regulate Imaging Liquid As Drug
- Fed. Circ. Judge Challenges USPTO Role In Biogen Appeal
- Calif. CBD Co. Sued After FDA Warning About Illegal Goods
- Justices Told Arthrex 'Uncertainty' Overshadows Immunity Bid
- Lieff Cabraser's Elizabeth Cabraser Talks About Opioids, VW
- New Talc Jury Gives J&J Chance To Stem Tide Of Legal Blows
- SEC Scores Early Win In Mass. Biotech CEO Fraud Suit
- 'Blocking Patent' Doctrine May Now Apply To All Technologies
- Fed. Circ. Vacates Samsung PTAB Win In Light Of Arthrex
- Jury Told Kite Wanted Sloan Kettering's Patients, Not Patent
- Doctor Linked To Insys Convicted On Kickback Charges
- Colo. CBD Vendor Latest To Face Class Action Over Legality
- Feds Can't Halt True Health's Ch. 11 Plan For Medicare Dispute
- Analysts Plead Not Guilty To Doctor's Office Ad Fraud Scheme
- Stinson Lands Former DOJ Health Care Fraud Enforcer
- Tufts Drops Sackler Name From Medical School Over Opioids
- Gov't Wants Justices To Tackle ERISA Preemption Case
- Allergan Says State Laws Doom Restasis Payors' Class Push
- Marijuana Magnate To Pay $4M In SEC Stock Boosting Suit
- Investors Say Aveo Pharma Can't Shake Stock-Drop Suit
- What Is A 'Reasonably Useful Form' For Production Of ESI?
- Big Data, Social Media Trigger More Life Science Mass Torts
- Bid Protest Spotlight: Tradeoffs, Venue, Ambiguity, Licenses
- Scrutiny Of Patient Assistance Program Funding Is Rising
- Fed. Circ.'s Arthrex Decision Should Apply Retroactively
- Jury Told 'Whole Field' Knows Kite Infringed Juno's Patent
- Hospital Groups Challenge HHS Pricing Transparency Rule
- Maine Says Hemp Rule Could Hold Back State's Farmers
- J&J Docs Show Its Talc Contained Asbestos, Expert Tells Jury
- Geico Accuses NY Pharmacy Of $1M No-Fault Insurance Fraud
- Full Fed. Circ. Passes On Enzo's Retroactive IPR Challenge
- Judge Holds Decision On Purdue Pharma CEO Bonus
- PTAB Allows J&J Unit To Amend Surgical Device Patent
- Insys Plan Disclosures OK'd On Road To Jan. Confirmation
- PTAB Rejects Agilent's Challenge Of Testing Kit Patent
- Innovative Collaborations Require Antitrust Flexibility
- IPO Benefits And Challenges For Early-Stage Biotech Cos.
- AstraZeneca Sells Rights To Embattled Bipolar Drug For $35M
- 'Puppet Master' Ran $1.8M Aegerion Drug Fraud, Jury Hears
- Possible Patent Typo Debated As Juno, Kite IP Trial Kicks Off
- 9th Circ. Revives Takeda Buyers' RICO Suit Over Actos Risk
- NJ Pharma Co. Settles Price-Fixing Charges For $3M
- 2 More CBD Cos. Accused Of Selling Illegal Products
- Rio Tinto Unit Tells Jury It Never Supplied J&J's Talc
- Attys Report Broad Support For Opioid MDL Negotiation Class
- Pittsburgh Utility Sued For Firing Man Over Medical Marijuana
- Patent Decision Highlights Cross-Appeal Considerations
- Pot Co. Harborside Takes $11M Tax Bill Battle To 9th Circ.
- Okla. Marijuana Ruling Underscores Broad Worker Projections
- Ex-Shkreli Employee Says Counterclaim Ignores Court Ruling
- Senate Committee Advances FDA Nominee
- Barnes & Thornburg Opens 3 Life Sciences IP Offices
- Ill. Cannabis Licensing Scheme Unconstitutional, Suit Says
- Insys Files New Ch. 11 Plan Reflecting Deal With DOJ, States
- FDA's Asbestos-In-Talc Finding Takes Stage In Latest J&J Trial
- Fed. Circ. Weighs Medical Device Indefiniteness Case
- Feds Seek Halt Of True Health Ch. 11 Plan Amid Medicare Row
- Covington, Fenwick Shape $3B Deal For California Drugmaker
- Walgreens Denies 'Fast Release' Pain Relievers Are Mislabeled
- Medical Supply Co. Slammed With Suit Over Data Breach
- Walgreens Is Latest To Sue Glumetza Makers Over Price Hikes
- CBD Co.'s Products Are Federally Illegal, Consumer Claims
- Cannabis Distributor Owes $6M For Hemp, Grower Says
- Pfizer Claims No Link To Generic-Drug Price-Fix Plot
- Mallinckrodt Hit With Cocaine Anesthetic Trade Secret Suit
- 1st Circ. Upholds Stripped Bonus For Fired Abiomed Exec
- Kisor May Be A New Dawn For Challenges To FDA Actions
- Covington-Led Immunotherapy Co. IFM Lands $56M Financing
- Proteon Therapeutics Investor Seeks To Halt $42M Merger
- Made In Canada: Why US Pot Is Tied To Its Northern Neighbor
- AGs Used Privileged Doc Again In Price-Fix Case: Pharma Co.